


Selpercatinib

02/20

ALTERNATE NAMES: 6-(2-hydroxy-2-methylpropoxy)-4-[6-[[6-(methoxypyridin-3-yl)methyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]pyridin-3-yl]pyrazolo[1,5-a]pyridine-3-carbonitrile; LOXO-292

CATALOG #: B2996-1 1 mg
B2996-5 5 mg

STRUCTURE:



MOLECULAR FORMULA: C₂₉H₃₁N₇O₃

MOLECULAR WEIGHT: 525.6

CAS NUMBER: 2152628-33-4

APPEARANCE: White to off-White powder

PURITY: >98%

SOLUBILITY: ~8 mg/ml in DMSO. Ultrasonication can be done to improve solubility.

DESCRIPTION: Selpercatinib is a RET kinase inhibitor with IC₅₀ values ranging from 1 nM to 4 nM for wild type and mutant RET kinase. It has shown promising results in early phase clinical trials for RET-driven lung tumours with enhanced clinical activity and better tolerability.

STORAGE TEMPERATURE: -20°C. Store in the dark. Product is light sensitive. Protect from air. Store under desiccating conditions.

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

REFERENCE: Ackermann, C.J., Stock, G., Tay, R., et al. Targeted Therapy For RET-Rearranged Non-Small Cell Lung Cancer: Clinical Development And Future Directions. *Onco Targets Ther.* 12:7857-7864 (2019).

RELATED PRODUCTS:

BBT-594 (Cat. No. B2114)
 EZSolution™ SU-5416 (Cat. No. 9492)
 Carbozantinib (Cat. No. 1935)
 BT-13 (Cat. No. B2576)
 BLU-667 (Pralsetinib) (Cat. No. B2548)

DISCLAIMER: *FOR RESEARCH USE ONLY! Not to be used on humans.*